Abstract：Objective To compare the clinical efficacy of Bisoprolol and Valsartan in the treatment of resistant hypertension. Methods A total of 96 patients with resistant hypertension admitted to Suzhou Hospital of Traditional Chinese Medicine in Anhui Province from June 2019 to June 2021 were selected as the research objects. They were divided into control group and experimental group by random number table method, with 48 cases in each group. The control group was treated with Valsartan, 80 mg/time, once a day on the basis of routine treatment. The experimental group was treated with Bisoprolol, 5 mg/time, once a day on the basis of routine treatment. Both groups were treated for four weeks. The clinical efficacy, and diastolic blood pressure (DBP), systolic blood pressure (SBP), inflammatory factors, lipid metabolism levels were compared between the two groups before and after treatment, and the occurrence of adverse drug reactions in the two groups was recorded. Results During the study, one case dropped out of the experimental group and two cases dropped out of the control group. There was no significant difference in clinical efficacy between the two groups (P＞0.05). After treatment, DBP and SBP of the two groups were lower than those before treatment, and the differences were statistically significant (P＜0.05). After treatment, the levels of high-sensitivity C-reactive protein, Salusin-β, and matrix metalloproteinase-3 in the two groups were lower than those before treatment, and those in the experimental group were lower than those in the control group, and the differences were statistically significant (P＜0.05). There was no significant difference in total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol between the two groups before and after treatment (P＞0.05). There was no significant difference in the total incidence of adverse drug reactions between the two groups (P＞0.05). Conclusion Bisoprolol and Valsartan have similar efficacy in the treatment of resistant hypertension, and they do not affect the blood lipid metabolism indexes of patients with resistant hypertension, with good safety, but Bisoprolol has more advantages in improving serum inflammatory factors in patients with resistant hypertension.
张伟 康黎明 叶挺. 比索洛尔与缬沙坦治疗顽固性高血压的临床效果比较研究[J]. 中国医药导报, 2023, 20(17): 69-72,77.
ZHANG Wei KANG Liming YE Ting. Comparative study on the clinical effect of Bisoprolol and Valsartan in the treatment of resistant hypertension. 中国医药导报, 2023, 20(17): 69-72,77.
京公网安备 11010502046598号